Novacyt

Novacyt Retained Earnings

The Retained Earnings of Novacyt (ALNOV.PA) as of Oct 9, 2026 is -52.89 M GBP. In the previous year, Retained Earnings was -11.70 M GBP — a change of 352.24% (lower).

Retained Earnings

-52.89 MGBP

YoY

352.24%

Last updated:

Retained Earnings of Novacyt is 2025 -52.89 M GBP. Retained Earnings of Novacyt was 2024 -11.70 M GBP. It decreases by 352.24% lower compared to the previous year.

The Novacyt Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-29.18 M GBP
Jan 1, 2019
-32.14 M GBP
Jan 1, 2020
96.92 M GBP
Jan 1, 2021
87.19 M GBP
Jan 1, 2022
60.84 M GBP
Jan 1, 2023
29.90 M GBP
Jan 1, 2024
-11.70 M GBP
Jan 1, 2025
-52.89 M GBP
The Novacyt Retained Earnings history
YEARRetained EarningsYoY
-52.89 MGBP+352.24%
-11.70 MGBP-139.11%
29.90 MGBP-50.85%
60.84 MGBP-30.22%
87.19 MGBP-10.04%
96.92 MGBP-401.55%
-32.14 MGBP+10.13%
-29.18 MGBP+2.97%
-28.34 MGBP+40.23%
-20.21 MGBP+7.21%
-18.85 MGBP+169.78%
-6.99 MGBP—
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Retained Earnings of Novacyt is -52.89 M GBP in 2025.

Retained Earnings of Novacyt changed from -11.70 M GBP to -52.89 M GBP, representing a 352.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Novacyt since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Novacyt historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novacyt

All Key Metrics — Novacyt